Equitable Holdings’s Ginkgo Bioworks DNA Stock Holding History

Equitable Holdings’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-48,379	Closed	-$402K	–	1707
2025 Q4	$402K	Sell	48,379 -33,900	-41%	-$365K	﹤0.01%	1192
2025 Q3	$1.2M	Buy	82,279 +21,465	+35%	+$257K	0.01%	785
2025 Q2	$684K	Buy	60,814 +3,500	+6%	+$27.1K	0.01%	915
2025 Q1	$327K	Buy	+57,314	New	+$584K	﹤0.01%	1061
2024 Q3	–	Sell	-280	Closed	-$3.74K	–	1268
2024 Q2	$3.74K	Sell	280 -9	-3%	-$269	﹤0.01%	1210
2024 Q1	$13.4K	Hold	289	–	–	﹤0.01%	1158
2023 Q4	$19.5K	Hold	289	–	–	﹤0.01%	1127
2023 Q3	$20.9K	Hold	289	–	–	﹤0.01%	1063
2023 Q2	$21.5K	Hold	289	–	–	﹤0.01%	1035
2023 Q1	$15.4K	Hold	289	–	–	﹤0.01%	972
2022 Q4	$19.5K	Sell	289 -25	-8%	-$2.3K	﹤0.01%	895
2022 Q3	$39K	Buy	314 +9	+3%	+$1.07K	﹤0.01%	859
2022 Q2	$29K	Hold	305	–	–	﹤0.01%	848
2022 Q1	$49K	Hold	305	–	–	﹤0.01%	864
2021 Q4	$101K	Hold	305	–	–	﹤0.01%	846
2021 Q3	$141K	Buy	+305	New	+$148K	﹤0.01%	821

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Equitable Holdings's DNA Position: Q1 2026 in Review

Equitable Holdings sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 48,379 shares — an estimated $402K sold.

Equitable Holdings first reported a position in DNA in Q3 2021 and held it in 16 quarters. The position peaked at $1.2M in Q3 2025. 175 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

Equitable Holdings reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
Equitable Holdings sold 48,379 Ginkgo Bioworks shares in Q1 2026, an estimated $402K.
Equitable Holdings first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 16 quarters.
Equitable Holdings's Ginkgo Bioworks position peaked at $1.2M in Q3 2025.
175 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Equitable Holdings's 13F filing for Q1 2026, filed 15 May 2026.